Searched for
NOVO SHARE PRICE
European shares rally as Middle East peace hopes drag oil prices lowerEuropean shares surged on Friday, driven by renewed hopes for a Middle East diplomatic breakthrough that lowered oil prices. The pan-Europe...- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- Global Market | European stocks rally as oil falls on hopes for US-Iran dealThe benchmark snapped a four-day losing streak on Thursday, as investors digested the European Central Bank's rate hike and largely looked...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- PE wars to billion-dollar IPO dreams, hospital sector is fighting fitMajor private equity firms are vying for a stake in Cloudnine, a leading maternity and paediatric care chain. This intense competition high...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Novo rebrands diabetes pill as Ozempic to tap blockbuster nameNovo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Global Markets | European equities log steep weekly losses with no resolution to MidEast conflictEuropean stocks saw a significant weekly drop Friday. Investors are concerned about growth and inflation due to Middle East conflict disrup...
- Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiativeRegeneron will reduce prices for its drugs on Medicaid. A cholesterol drug, Praluent, will be available for USD 225 on Trump's discounted d...
- US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats upKailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo NordiskThe US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Nov...
- Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge genericsNovo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments...
- Novo Nordisk plans to cut price of Ozempic as generics hit marketNovo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmake...
- Obesity drug maker Novo Nordisk ousts CEO as competition weighsNovo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity d...
- Novo Nordisk's stock rises as Ozempic beat analysts' expectations in salesIn its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.
Load More
